92 related articles for article (PubMed ID: 16729120)
41. New PPARgamma ligands based on 2-hydroxy-1,4-naphthoquinone: computer-aided design, synthesis, and receptor-binding studies.
Sundriyal S; Viswanad B; Bharathy E; Ramarao P; Chakraborti AK; Bharatam PV
Bioorg Med Chem Lett; 2008 Jun; 18(11):3192-5. PubMed ID: 18482837
[TBL] [Abstract][Full Text] [Related]
42. Partial agonists activate PPARgamma using a helix 12 independent mechanism.
Bruning JB; Chalmers MJ; Prasad S; Busby SA; Kamenecka TM; He Y; Nettles KW; Griffin PR
Structure; 2007 Oct; 15(10):1258-71. PubMed ID: 17937915
[TBL] [Abstract][Full Text] [Related]
43. Design of selective nuclear receptor modulators: RAR and RXR as a case study.
de Lera AR; Bourguet W; Altucci L; Gronemeyer H
Nat Rev Drug Discov; 2007 Oct; 6(10):811-20. PubMed ID: 17906643
[TBL] [Abstract][Full Text] [Related]
44. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
[TBL] [Abstract][Full Text] [Related]
45. Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists.
Ahn JH; Shin MS; Jung SH; Kang SK; Kim KR; Rhee SD; Jung WH; Yang SD; Kim SJ; Woo JR; Lee JH; Cheon HG; Kim SS
J Med Chem; 2006 Jul; 49(15):4781-4. PubMed ID: 16854085
[TBL] [Abstract][Full Text] [Related]
46. Novel silicon-containing analogues of the retinoid agonist bexarotene: syntheses and biological effects on human pluripotent stem cells.
Bauer JB; Lippert WP; Dörrich S; Tebbe D; Burschka C; Christie VB; Tams DM; Henderson AP; Murray BA; Marder TB; Przyborski SA; Tacke R
ChemMedChem; 2011 Aug; 6(8):1509-17. PubMed ID: 21726055
[TBL] [Abstract][Full Text] [Related]
47. A short series of antidiabetic sulfonylureas exhibit multiple ligand PPARgamma-binding patterns.
Arrault A; Rocchi S; Picard F; Maurois P; Pirotte B; Vamecq J
Biomed Pharmacother; 2009 Jan; 63(1):56-62. PubMed ID: 18280694
[TBL] [Abstract][Full Text] [Related]
48. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
49. PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development.
Tanis SP; Colca JR; Parker TT; Artman GD; Larsen SD; McDonald WG; Gadwood RC; Kletzien RF; Zeller JB; Lee PH; Adams WJ
Bioorg Med Chem; 2018 Dec; 26(22):5870-5884. PubMed ID: 30429097
[No Abstract] [Full Text] [Related]
50. Synthesis and anti-inflammatory activity of new arylidene-thiazolidine-2,4-diones as PPARgamma ligands.
Barros CD; Amato AA; de Oliveira TB; Iannini KB; Silva AL; Silva TG; Leite ES; Hernandes MZ; Alves de Lima Mdo C; Galdino SL; Neves Fde A; Pitta Ida R
Bioorg Med Chem; 2010 Jun; 18(11):3805-11. PubMed ID: 20471839
[TBL] [Abstract][Full Text] [Related]
51. Molecular targets of organotin compounds in endocrine disruption: do organotin compounds function as aromatase inhibitors in mammals?
Nakanishi T; Nishikawa J; Tanaka K
Environ Sci; 2006; 13(2):89-100. PubMed ID: 16788560
[TBL] [Abstract][Full Text] [Related]
52. Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma)-specific agonist, as a modulator in experimental acute pancreatitis.
Celiński K; Madro A; Prozorow-Król B; Korolczuk A; Cichoz-Lach H; Słomka M; Korobowicz E
Med Sci Monit; 2009 Jan; 15(1):BR21-9. PubMed ID: 19114961
[TBL] [Abstract][Full Text] [Related]
53. [Challenge of creating single-agents for the treatment of type 1 and 2 diabetes by targeting retinoid X receptor].
Kakuta H
Yakugaku Zasshi; 2011; 131(6):917-23. PubMed ID: 21628978
[TBL] [Abstract][Full Text] [Related]
54. Bexarotene prodrugs: targeting through cleavage by NQO1 (DT-diaphorase).
Schäfer A; Burstein ES; Olsson R
Bioorg Med Chem Lett; 2014 Apr; 24(8):1944-7. PubMed ID: 24666648
[TBL] [Abstract][Full Text] [Related]
55. Retinoids and PPAR agonists: Promising partners in neurodegenerative diseases?
Riancho J
Free Radic Biol Med; 2016 Aug; 97():616-617. PubMed ID: 27470447
[No Abstract] [Full Text] [Related]
56. Competitive Binding Assay with an Umbelliferone-Based Fluorescent Rexinoid for Retinoid X Receptor Ligand Screening.
Yamada S; Kawasaki M; Fujihara M; Watanabe M; Takamura Y; Takioku M; Nishioka H; Takeuchi Y; Makishima M; Motoyama T; Ito S; Tokiwa H; Nakano S; Kakuta H
J Med Chem; 2019 Oct; 62(19):8809-8818. PubMed ID: 31483660
[TBL] [Abstract][Full Text] [Related]
57. Synthesis of
Shibahara O; Watanabe M; Yamada S; Akehi M; Sasaki T; Akahoshi A; Hanada T; Hirano H; Nakatani S; Nishioka H; Takeuchi Y; Kakuta H
J Med Chem; 2017 Aug; 60(16):7139-7145. PubMed ID: 28753292
[TBL] [Abstract][Full Text] [Related]
58. [Structural insights of PPARgamma].
Kato S; Takada I
Nihon Rinsho; 2010 Feb; 68(2):176-9. PubMed ID: 20158081
[No Abstract] [Full Text] [Related]
59. Computer-Assisted Discovery of Retinoid X Receptor Modulating Natural Products and Isofunctional Mimetics.
Merk D; Grisoni F; Friedrich L; Gelzinyte E; Schneider G
J Med Chem; 2018 Jun; 61(12):5442-5447. PubMed ID: 29901398
[TBL] [Abstract][Full Text] [Related]
60. Elusive Conformational Dynamics of PPARγ Inactivation Tied Down by Chemical Cross-Linking.
Mohr JP; Bruce JE
Structure; 2018 Nov; 26(11):1425-1427. PubMed ID: 30403991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
